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	Key neuropathological changes associated with late-onset dementia are not fully understood. Population-based longitudinal studies offer an opportunity to step back and examine which pathological indices best link to clinical state. CC75C is a longitudinal study of the population aged 75 and over at baseline in Cambridge, UK. We report on the first 213 participants coming to autopsy with sufficient information for an end of life dementia diagnosis. Clinical diagnosis was ascertained by examining retrospective informant interviews, survey responses, and death certificates according to DSM-IV criteria. The neuropathological protocol was based on the Consortium to Establish a Registry of Alzheimer’s Disease (CERAD). Clinical dementia was present in 113 participants (53%): 67% with Alzheimer’s disease, 4% vascular dementia, 22% mixed dementia, and 1% dementia with Lewy bodies. As Alzheimer-type pathology was common, the mutually blinded clinical and neuropathological diagnoses were not strongly related. Multivariable analysis identified associations between dementia during life and entorhinal cortex neuritic plaques, hippocampal diffuse plaques, neocortical neurofibrillary tangles, white matter pallor, Lewy bodies, and hippocampal atrophy. These results were consistent in those with clinical Alzheimer’s disease. Vascular pathologies, especially microinfarcts, were more common in those with clinical diagnoses including vascular dementia. Alzheimer-type and cerebrovascular pathology are both common in the very old. A greater burden of these pathologies, Lewy bodies, and hippocampal atrophy, are associated with a higher risk of, but do not define, clinical dementia in old age. 





	The “oldest-old” are the fastest-growing population group in developed countries and also have the greatest incidence of dementia [1]. Hence there is a need to improve the understanding of dementia and its underlying neuropathology in extreme old age. 
	Few population-based or community-based studies have compared dementia status with neuropathological findings in brain tissue at autopsy  ADDIN EN.CITE [2, 3]. Most of these studies include brain donors aged 65 years or older, with few including donors aged over 80 only  ADDIN EN.CITE [4, 5]. A subset has considered multiple pathologies together in association with dementia  ADDIN EN.CITE [3, 5-8], of which three are population-based studies; two in the UK  ADDIN EN.CITE [5, 8] and one in Hawaii [6]. Furthermore, few of these studies have been able to compare neuropathology across clinically diagnosed dementia sub-types  ADDIN EN.CITE [4, 7, 9]. 
	Each of the studies investigating multiple neuropathologies and clinical dementia in older people found a high prevalence of both Alzheimer-type pathology and vascular pathology, often ‘mixed’, in those with and without dementia at death, and accordingly only moderate association between the burden of neuropathology and dementia  ADDIN EN.CITE [3, 5-8]. Some evidence suggests that this relationship becomes even less clear with increasing age  ADDIN EN.CITE [10, 11]. We sought to examine the neuropathological correlates of dementia and its clinical sub-types in the very old by updating a previous report from a population-based study of dementia  ADDIN EN.CITE [5]. 

METHODS
The cohort sample and clinical information
	The Cambridge City over-75s Cohort (CC75C) study is a longitudinal population-based study of cognition and function in advanced old age (http://www.cc75c.group.cam.ac.uk)  ADDIN EN.CITE [12, 13]. The CC75C is the one of three European population-based studies that forms EClipSE (Epidemiological Clinicopathological Studies in Europe, http://www.eclipsestudy.eu). Beginning in the mid-1980s, the CC75C study enrolled 2,166 participants aged 75 or older in Cambridge, UK. Participants were first contacted by letter through general practices geographically and socially representative of the city overall, then approached in person and a response rate of 95% was achieved. The sample’s age-specific gender distribution and residential status closely matched national population data for that period. There have been 23 years of follow-up to date, with repeated interview waves every few years. The main cause of attrition has been mortality, which accounts for 76% of the loss to follow-up from the study overall and only 2% of the full cohort remain in the latest survey.
	In the initial phase of the study the full-sample surveys were followed by intensive examination of sub-samples using the Cambridge Diagnostic Examination for the Elderly (CAMDEX) [14], a psychiatrist administered assessment that also includes a proxy informant interview. Participants were sampled for intensive CAMDEX interviews on the basis of Mini-Mental State Examination (MMSE)  ADDIN EN.CITE [15] scores suggesting low to moderate cognitive function (MMSE scores 0–23). A proportion of participants with MMSE scores suggesting mild or minimal cognitive impairment were also assessed (a random 1 in 4 of individuals with MMSE scores 24–25). Besides the in-depth CAMDEX assessments made on many donors, retrospective interviews were sought with relatives after a donor’s death to obtain further information on the period between the participant’s last interview and death. 
	A consensus diagnosis for dementia status at death consistent with DSM-IV criteria [16] was agreed by two clinicians (TD and CB) using postmortem review of all interviews including proxy informant data, death certificates, and retrospective informant data after death, but blinded to neuropathology findings. Dementia was rated by severity and where possible sub-types were identified. Sub-type diagnoses used DSM-IV criteria and were consistent with recognized diagnostic systems including the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorder Association (NINDS-ADRDA) [17] and the third consortium for dementia Lewy bodies  ADDIN EN.CITE [18] criteria. Relatively few individuals had magnetic resonance or functional neuroimaging data.

Brain donation programme
	Approaching participants for possible enrollment into the study’s brain donation programme focused initially on people taking part in the intensive CAMDEX phase. This included an enriched sample of people with dementia, rapid cognitive decline, and ‘super-normals’ who were high functioning, as well as a random selection of the remainder. The recruitment methods and high rates of consent from participants, assent from relatives and successful collection have been described previously [19]. Subsequently participants whose MMSE scores suggested normal to high cognitive function were also recruited to the brain donation programme to ensure the sample included the full population spectrum. Although clinically diagnosed dementia assessments could not be made for the full cohort, the distribution of MMSE scores in the baseline sample closely matches those of the brain donor sample.

Neuropathological assessment
	After death, the brains were removed as soon as feasible in the local mortuary. The brains were cut in the sagittal plane. One hemisphere was dissected coronally into approximately one cm slices, macroscopically examined, and snap frozen at -80C. Macroscopical vascular burden was assessed by the number, size, and location of visible macrovascular lesions in any area. The age of the infarct or whether they were present in grey or white matter was not noted. The arterial distribution for the largest infarct involved was recorded. Number of lacunes was recorded in categories of 0, 1-4, 5-9, or 10 or more in each of the following locations: basal ganglia, thalamus, cerebral white matter, brainstem, and other. The other half of the brain was formalin fixed for at least six weeks. For diagnostic purposes, blocks for paraffin embedding were taken from: the hippocampus (at the level of the lateral geniculate body), entorhinal cortex (at the level of the mamillary body), frontal, temporal, parietal, and occipital lobes, the basal ganglia, thalamus, pons, medulla, cerebellum, and from two levels of the midbrain. The tissue blocks included subcortical white matter, deep cerebral white matter, and the internal capsule.
	Ten micrometer thick sections were stained with haematoxylin and eosin to qualitatively assess white matter pallor, perivascular gliosis, presence of microinfarcts, and microvascular changes in each area sampled. Separate scores were recorded in white and grey matter for V-R space expansion, perivascular gliosis, and microinfarcts. Tau, amyloid-β protein, and Lewy body pathology was assessed on immunohistochemical preparations using antibodies obtained from the Cambridge Brain Bank Laboratory. Anti-tau antibody (mAb 11.57) was used to immunostain neurofibrillary tangles, neuritic plaques, and dystrophic neurites. Slides stained with anti-ubiquitin antibody (pAb BR 251 DAKO Z0458, early cases) or anti-α-synuclein antibody (Biomol International SA3400, later cases) and slides stained with haematoxylin and eosin were used to detect Lewy bodies. Diffuse plaques were assessed using anti-amyloid-β antibody (DAKO (M872) Clone 6F/3D). Diffuse amyloid-β-reactive plaques were distinguished from neuritic plaques by the presence or absence of dystrophic neurites. Diffuse plaques were recorded as amyloid deposits in the CERAD version used. All sections were counterstained with Ehrlich’s haematoxylin with diaminobenzidine as the chromagen.
	The protocol of the Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) [20] was followed. Typical Alzheimer’s lesions were considered by taking the CERAD ratings for neuritic plaques, diffuse plaques, and neurofibrillary tangles in the following areas: entorhinal, hippocampal, frontal, temporal, parietal, and occipital. Ratings for tau reactive plaques and tangles were estimated according to Braak Staging [21] and ratings for diffuse amyloid-β-reactive plaques were estimated according to the age dependent CERAD protocol [20] for all areas. Microinfarcts, irrespective of age of infarct, were assessed by their presence or absence in the following areas: entorhinal, hippocampal, frontal, temporal, parietal, occipital, deep grey, and ‘other’. White matter pallor was assessed as present or absent in the occipital, parietal, frontal, temporal cortices, and as pallor in the deep white matter or internal capsule in slides containing the basal ganglia. Lewy bodies were assessed by their presence or absence in entorhinal, hippocampal, frontal, or temporal areas and, in addition, in the substantia nigra, nucleus basalis, dorsal raphe nucleus, locus coeruleus, and dorsal vagal nucleus. Based on haematoxylin and eosin and Congo Red stains amyloid-β-reactive pathology in blood vessel walls was assessed in the meningeal and parenchymal areas of the hippocampus, frontal, temporal, parietal, and occipital areas and rated as sparse (just detectable amounts), moderate (obvious amyloid but without an effect on the vessel lumen, without leakage of blood and without inflammation), or severe (obvious amyloid with an effect on the vessel lumen, leakage of blood and/or inflammation). Small-vessel disease was defined as presence of white matter pallor, perivascular gliosis or ‘other’ microscopic vascular disease. All assessments were performed blind to clinical status by JHX or neuropathologists at Addenbrooke’s Hospital, Cambridge, UK. 

Statistical methods
	As of October 2008 the first 224 donations in the CC75C brain donor program had complete neuropathology reports available for analysis (dataset version 3.0). Of these, 11 were excluded from this analysis due to insufficient evidence for a clinical diagnosis of dementia. Dementia status was defined as mild or more severe dementia versus minimal or no dementia. Minimal dementia refers to the CAMDEX category of that name [14], a limited and variable cognitive impairment falling short of a clinical diagnosis of dementia.
	The frequencies of demographic and neuropathological variables were examined across clinical dementia and age groups. Age at death was categorized into four groups: less than 85 years old, 86-89, 90-94, and 95 or older. The lowest two age groups were combined in all further analyses due to small frequencies of participants aged less than 85 years at death. Neuropathological variables with a gradient for severity were also dichotomized due to small frequencies of participants in the four groups. Brain weight was categorized based on tertiles of the sex-specific brain-weight distribution in the sample to provide low, average, and high for sex. Logistic regression was performed on those variables with sufficient numbers to predict dementia status adjusting for age at death. A multivariable model was built from all identified demographic and neuropathological variables using a backwards stepwise approach retaining age and those variables contributing to the model at a p<0.20 significance level. 
	The frequencies of the identified neuropathological variables were also examined across clinical dementia sub-types. Odds ratios adjusted for age were estimated for those neuropathological variables included in the final multivariable dementia model to compare participants with any clinical diagnosis of Alzheimer's disease (pure or mixed), and separately participants with any clinical diagnosis of vascular dementia (pure or mixed), to those without dementia. These variables were also used to build two separate multivariable models via a backwards stepwise approach retaining age and variables with p<0.20 in the final models. All analyses were conducted in Stata (Intercooled Version 9.2).

RESULTS
	The median age at death of the 213 participants analyzed was 91 (range 81 to 101 years) and approximately 70% were women (Table 1). The average length of study follow-up was 9 years (SD=4) with a median time from last interview to death of 1.6 years (IQR=0.8-2.5). The median time from last survey until death did not differ significantly across dementia status or age groups. Most of the participants (75%) had complete retrospective informant interviews to aid in the clinical dementia diagnosis. A clinical rating of dementia at mild or greater severity was diagnosed for 113 participants (53%). Of these, 76 (67%) had a primary clinical diagnosis of Alzheimer’s disease, 4 (4%) of vascular dementia, 25 (22%) of mixed dementia, 1 (1%) of dementia with Lewy bodies, and 7 (6%) as dementia from other causes. Participants with clinical dementia were more likely to be women and older.
	Table 2 quantifies the limited extent to which diagnoses made by pathologists, blind to the clinical status, related to clinical status (Table 2). Analyses examined relationships both with neuropathological diagnosis ranked first and all diagnoses included in the neuropathologist’s report. Most participants (81%) were rated as having pathology consistent with Alzheimer's disease as their first neuropathological diagnosis (85% of those with clinical dementia, but almost as common—76%—amongst those without). Only 7% of participants without clinical dementia were given a first neuropathological diagnosis of a normal brain. However, both Braak staging and the age-dependent CERAD scores were more severe in those with dementia (p<0.001) (Figure 1).
	Cerebrovascular (Figure 2) and Alzheimer-type (Figure 3) pathology were generally common across all participants and somewhat more severe in those with dementia. Compared to the neocortex, neuritic plaques and tangles were more frequently detected in the hippocampus, but generally less frequently detected in the entorhinal cortex. Lewy bodies were observed in 20% of participants with clinical dementia. Lewy bodies were most frequently detected in the brainstem (13%) and less frequently in the cortex (5%) and subcortex (3%). Evidence of atrophy was common (47% in the neocortex and 41% in the hippocampus). Beyond clinical dementia status, there were generally no significant differences in pathological burden across age and sex (data not shown). We observed considerable overlap in pathology between those with clinical dementia and those without. For example of those without clinical dementia, 37% had moderate or severe neocortical diffuse plaques and 64% had moderate or severe hippocampal tangles. In addition there were participants with clinical dementia, yet a relatively low burden of AD-pathology. For example, 9% had no neuritic plaques detected and 13% no diffuse plaques detected (in the neocortex, hippocampus, or entorhinal cortex). 
	In the bivariable analysis (adjusted for age), low brain weight for sex, neocortical and hippocampal atrophy, Lewy bodies, congophilic amyloid angiopathy (CAA), and all Alzheimer-type pathology variables examined were significantly associated with clinical dementia (Table 3). Of the cerebrovascular variables, only white matter pallor and small-vessel disease were significantly associated with clinical dementia. Vascular pathologies were common in this sample, and, for example, over 85% of participants had either Virchow-Robin (V-R) space expansion or arteriolarsclerosis. Most participants with clinical dementia had small vessel disease (58%), arteriolarsclerosis (75%), V-R space expansion (73%), microinfarcts (56%), or white matter pallor (55%). In the multivariable analysis, entorhinal cortex neuritic plaques, hippocampal diffuse plaques, neocortical neurofibrillary tangles, white matter pallor, Lewy bodies, and hippocampal atrophy were significantly and independently associated with clinical dementia. 





	In this analysis examining postmortem neuropathology and clinical dementia in an extremely aged population sample, associations were found between neuritic plaques, diffuse plaques, neurofibrillary tangles, cerebrovascular pathologies, and clinical dementia, and also with clinical dementia sub-types, confirming earlier findings from this population for the first 101 brains  ADDIN EN.CITE [5]. The overall burden of pathology was generally high across all participants with most brains showing sufficiently extensive lesions to suggest pathological classification of dementia, whether the donor had been clinically demented before death or not. However, participants with a clinical diagnosis of dementia did generally have a greater burden of pathology than those without dementia. Vascular and Lewy pathologies were reasonably common, but clinical diagnoses of these as ‘pure’ disorders was very rare, rather they appeared in combination within individuals. 
	The strengths of this study include the availability of consensus diagnoses of dementia, a long period of follow-up from a sizeable population-based ageing cohort, and the ability to examine a wide range of neuropathologies assessed blind to clinical status. Although participants into the brain donation program were not selected at random, they are representative of the population at baseline and the prevalence of dementia at death is as expected in this age group [22]. The statistical approach included multivariable modeling which allowed us to compare the neuropathological features simultaneously. We were also able to confirm our clinical dementia associations in those with Alzheimer’s disease and highlight differences in those with vascular dementia.
	Although the diagnosis of dementia was not confirmed by a diagnostic clinical interview, the potential for misclassification is small. Consensus was reached by clinical experts using a wide range of clinical and survey information, the timing of which was generally close to death. It was usually clear when dementia was definitely present and the interview questions asked of relatives after death specifically excluded clear terminal decline. However, there was a group in whom the boundary between decline and dementia in the oldest-old was difficult to formally diagnose. We have reported previously on the continuum of cognitive change in this population over time and the non-demented therefore represent this range [23]. 
	Our study used a neuropathological resource generated from the autopsy diagnostic procedure used in the CC75C study in which areas of interest were sampled only once. This leads to a lower chance of sampling the pathology of interest and therefore our results are likely to underestimate any association. This sampling protocol also limits our ability to analyze in detail the effect of location on dementia for each lesion type. Dichotomizing the grading of vascular pathology is a coarse measure and again may lead to an underestimate of any association.
	As expected, the associations between neuritic plaques and neurofibrillary tangles and clinical dementia were the strongest of all pathologies within this sample of over-80-year-olds. We did not find either to be a superior predictor of clinical dementia nor did we intend to test this; rather we found that they both together improved our ability to classify clinical dementia status at death. The burden of neuritic plaques, diffuse plaques, and neurofibrillary tangles in the three brain areas examined were highly correlated. For example, 85% of those with moderate or severe neocortical neuritic plaques also had moderate or severe neocortical neurofibrillary tangles. Neuritic plaques, diffuse plaques, and tangles in the different brain areas had strong associations with clinical dementia when considered separately, and the strong correlations amongst them meant that the multivariable model could be similarly predictive by including different combinations of these variables. The final multivariable model (table 3) shows the strongest combinations of predictors from the data available. There was very little difference in the predictive ability of the multivariable model when including either neocortical plaques or tangles separately, i.e., the multivariable model with neocortical tangles but no other measure of plaques or tangles explained around 29% of the variance (measured by pseudo R-squared) in clinical dementia status, whereas the multivariable model with neocortical plaques (but no other measure of plaques or tangles) explained around 28%. The final multivariable model (table 3) explained 36% of the variation in clinical dementia status.
	Atrophic changes of the hippocampus are typically regarded as an early sign of Alzheimer's disease [24] and in a prospective study of people also aged over 80 years hippocampal sclerosis was also found to be a common pathological feature of dementia [25]. We lacked information on hippocampal sclerosis, but did observe a strong association between hippocampal atrophy and clinical dementia, in particular clinically diagnosed Alzheimer’s disease.
	Our observed frequencies of 20% and 8% Lewy bodies in the dementia and non-dementia groups, respectively, are consistent with other findings given our older sample  ADDIN EN.CITE [3, 7, 8, 26]. Similar to a community-based US study [3], yet contrary to other studies  ADDIN EN.CITE [6-8], we identified significantly more Lewy bodies in the dementia group than in the non-dementia group. However, we could not confirm the finding of increased Alzheimer-type pathology in those with Lewy body pathology in the oldest-old as observed in a population-based study in Japan  ADDIN EN.CITE [25]. 
	White matter lesions have been reported in relation to dementia previously  ADDIN EN.CITE [9, 27] and cognitive decline [28]. We observed increased frequencies of white matter pallor in participants with clinical dementia. However, others have argued the association with white matter lesions and cognition is inconsistent, and instead microscopic infarcts markedly impact cognition [29]. In our sample, very similar associations with dementia were also observed for microinfarcts and 69% of those with white matter pallor also had microinfarcts. Microscopic infarcts were observed to be an independent predictor of dementia status in three separate longitudinal studies of aging in the US  ADDIN EN.CITE [3, 6, 30]. Multiple disseminated microinfarcts are reported to perhaps represent the most common morphologic features of vascular dementia [31] and we also observed strong associations between microinfarcts and clinically diagnosed vascular dementia (pure or mixed).
	More severe CAA was observed in participants with clinical dementia than in those without (26% versus 4% moderate or severe, respectively), but the association was not significant after adjusting for the other neuropathological features. CAA has been implicated as a likely cause of small infarcts, microinfarcts, and incomplete infarctions in the deep white matter [32]. Of the 33 participants with CAA in our sample, 73% had white matter pallor or microinfarcts and these factors were more strongly associated with clinical dementia in this study. Several studies of the oldest old suggest that microvascular pathology is a significant factor in cognitive status and dementia  ADDIN EN.CITE [33]; more detailed studies are required to investigate this. 
	As also observed in old age in other studies  ADDIN EN.CITE [8, 34], there was considerable overlap in terms of pathology both between those people clinically diagnosed as not having dementia and those with dementia, and between those diagnosed as having different sub-types of clinical dementia. For example Alzheimer-type pathology was noted as the main neuropathology diagnosis for 76% of the clinically non-demented, barely less common than in the clinically demented (85%). However, participants with a clinical diagnosis of vascular or mixed dementia had a greater burden of vascular pathology than those with clinical Alzheimer’s disease or no dementia. The group diagnosed as having mixed dementia was intermediate between Alzheimer’s and vascular dementia, though rather closer to the Alzheimer group in the extent of vascular pathology. Given that two-thirds of our sample with clinical dementia had been given an Alzheimer’s disease diagnosis, the associations detected with dementia may have been driven by this. The burden of vascular pathology observed in our study is consistent with others, although lower than in another UK population-based study [8], perhaps partly due to slight differences in definitions of small-vessel disease. Standardized protocols to grade vascular pathology are required to ease cross-study comparisons. However, our vascular dementia findings appear similar to others [31]. 
	We detected relatively few age associations with pathology in this sample, which is not unexpected since we are reporting the prevalence of each pathology at death and a high level of pathology may be a driver of mortality in this age group. All the donors were also in a fairly narrow “older old” age range. The potential for less association between pathology and dementia in the oldest old compared to the younger old has been commented on elsewhere [10] and new research suggests that neuropathological distinctions between those with and without dementia narrow as age increases [11]. 

CONCLUSIONS AND IMPLICATIONS
	Alzheimer-type and cerebrovascular pathology are common in the oldest old and considerable overlap exists in pathological burden in those with and without clinical dementia at death. Neuritic plaques, diffuse plaques, neurofibrillary tangles, hippocampal atrophy, white matter pallor, and Lewy bodies were strongly associated with dementia in this sample, but cannot be assumed to be responsible for all dementia in the oldest old. Our results suggest that progression to dementia in the oldest old is a complex interplay of many factors, some of which may as yet be unknown. These findings have implications for public health, confirming the likely importance of vascular factors even in the oldest age groups, as cerebrovascular disease is potentially preventable. Strategies to target cerebral microinfarcts, in particular, could potentially decrease the incidence of dementia in this age group, although such prevention would also be likely to lead to longer life and increased risk of associated brain pathology.

ACKNOWLEDGMENTS
	The authors wish to thank particularly the study respondents, their families, friends and the staff in many care homes and collaborating general practices without whose help none of this research would be possible. The current research team gratefully acknowledge the contributions of previous investigators, past research team members, Addenbrooke’s Hospital mortuary staff and the helpful comments on earlier drafts of this paper from current collaborators (see full list on CC75C study website http://www.cc75c.group.cam.ac.uk/pages/studypersonnel/default.htm). 
	Each phase of the CC75C study has been approved by Cambridge Research Ethics Committee.
	We thank all the past CC75C sponsors for financial support spanning two decades (see http://www.cc75c.group.cam.ac.uk/pages/grant/default.htm for full list of project grants) and the BUPA Foundation for current support under their Health and Care of Older People grant. CC75C is a member study of the Cambridgeshire and Peterborough Collaboration for Leadership in Applied Health Research & Care (CLAHRC) and the Brain Bank is supported by the National Institute for Health Research Cambridge BioMedical Research Centre. The funders had no role in the study design, analysis or writing this paper. 
	Authors’ disclosures available online (http://www.j-alz.com/disclosures/view.php?id=80).

REFERENCES
[1]	Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.[2]	Zaccai J, Ince P, Brayne C (2006) Population-based neuropathological studies of dementia: design, methods and areas of investigation--a systematic review. BMC Neurol 6, 2.[3]	Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine TJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 62, 406-413.[4]	Polvikoski T, Sulkava R, Myllykangas L, Notkola IL, Niinisto L, Verkkoniemi A, Kainulainen K, Kontula K, Perez-Tur J, Hardy J, Haltia M (2001) Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 56, 1690-1696.[5]	Xuereb JH, Brayne C, Dufouil C, Gertz H, Wischik C, Harrington C, Mukaetova-Ladinska E, McGee MA, O'Sullivan A, O'Connor D, Paykel ES, Huppert FA (2000) Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci 903, 490-496.[6]	White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR (2002) Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 977, 9-23.[7]	Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204.[8]	(2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357, 169-175.[9]	Bigler ED, Lowry CM, Kerr B, Tate DF, Hessel CD, Earl HD, Miller MJ, Rice SA, Smith KH, Tschanz JT, Welsh-Bohmer K, Plassman B, Victoroff J (2003) Role of white matter lesions, cerebral atrophy, and APOE on cognition in older persons with and without dementia: the Cache County, Utah, study of memory and aging. Neuropsychology 17, 339-352.[10]	Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65, 1211-1217.[11]	Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, for the Medical Research Council Cognitive Function and Ageing Study (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.[12]	Brayne C, Huppert F, Paykel E, Gill C (1992) The Cambridge Project for Later Life: design and preliminary results. Neuroepidemiology 11 Suppl 1, 71-75.[13]	Fleming J, Zhao E, O'Connor DW, Pollitt PA, Brayne C (2007) Cohort profile: the Cambridge City over-75s Cohort (CC75C). Int J Epidemiol 36, 40-46.[14]	Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149, 698-709.[15]	Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.[16]	American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC.[17]	McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.[18]	McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.[19]	Beardsall L, Barkley C, O'Sullivan A (1992) The response of elderly community residents to request for brain donation: An interim report. Int J Geriatr Psychiatry 7, 199-201.[20]	Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.[21]	Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16, 271-278; discussion 278-284.[22]	Brayne C, Gao L, Dewey M, Matthews FE (2006) Dementia before death in ageing societies--the promise of prevention and the reality. PLoS Med 3, e397.[23]	Brayne C, Gill C, Paykel ES, Huppert F, O'Connor DW (1995) Cognitive decline in an elderly population--a two wave study of change. Psychol Med 25, 673-683.[24]	Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, Mistur R, Tsui WH, de Leon MJ (2008) Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging, in press.[25]	Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E, Aronson MK, Crystal HA (1994) Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol 88, 212-221.[26]	Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T (2003) Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 106, 374-382.[27]	Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2004) Cerebral white matter lesions and the risk of dementia. Arch Neurol 61, 1531-1534.[28]	Sitoh YY, Sahadevan S (2004) Clinical significance of cerebral white matter lesions in older Asians with suspected dementia. Age Ageing 33, 67-71.[29]	Gold G, Kovari E, Hof PR, Bouras C, Giannakopoulos P (2007) Sorting out the clinical consequences of ischemic lesions in brain aging: a clinicopathological approach. J Neurol Sci 257, 17-22.[30]	Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ (2008) Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 64, 168-176.[31]	Jellinger KA (2008) The pathology of "vascular dementia": a critical update. J Alzheimers Dis 14, 107-123.[32]	Olichney JM, Hansen LA, Lee JH, Hofstetter CR, Katzman R, Thal LJ (2000) Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease. Ann N Y Acad Sci 903, 138-143.[33]	Imhof A, Kovari E, von Gunten A, Gold G, Rivara CB, Herrmann FR, Hof PR, Bouras C, Giannakopoulos P (2007) Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? J Neurol Sci 257, 72-79.[34]	Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA (2008) Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 67, 523-531.
[2]	Zaccai J, Ince P, Brayne C (2006) Population-based neuropathological studies of dementia: design, methods and areas of investigation--a systematic review. BMC Neurol 6, 2.
[3]	Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine TJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 62, 406-413.
[4]	Polvikoski T, Sulkava R, Myllykangas L, Notkola IL, Niinisto L, Verkkoniemi A, Kainulainen K, Kontula K, Perez-Tur J, Hardy J, Haltia M (2001) Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 56, 1690-1696.
[5]	Xuereb JH, Brayne C, Dufouil C, Gertz H, Wischik C, Harrington C, Mukaetova-Ladinska E, McGee MA, O'Sullivan A, O'Connor D, Paykel ES, Huppert FA (2000) Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci 903, 490-496.
[6]	White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR (2002) Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 977, 9-23.
[7]	Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204.
[8]	(2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357, 169-175.
[9]	Bigler ED, Lowry CM, Kerr B, Tate DF, Hessel CD, Earl HD, Miller MJ, Rice SA, Smith KH, Tschanz JT, Welsh-Bohmer K, Plassman B, Victoroff J (2003) Role of white matter lesions, cerebral atrophy, and APOE on cognition in older persons with and without dementia: the Cache County, Utah, study of memory and aging. Neuropsychology 17, 339-352.
[10]	Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65, 1211-1217.
[11]	Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, for the Medical Research Council Cognitive Function and Ageing Study (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
[12]	Brayne C, Huppert F, Paykel E, Gill C (1992) The Cambridge Project for Later Life: design and preliminary results. Neuroepidemiology 11 Suppl 1, 71-75.
[13]	Fleming J, Zhao E, O'Connor DW, Pollitt PA, Brayne C (2007) Cohort profile: the Cambridge City over-75s Cohort (CC75C). Int J Epidemiol 36, 40-46.
[14]	Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149, 698-709.
[15]	Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
[16]	American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC.
[17]	McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
[18]	McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.
[19]	Beardsall L, Barkley C, O'Sullivan A (1992) The response of elderly community residents to request for brain donation: An interim report. Int J Geriatr Psychiatry 7, 199-201.
[20]	Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
[21]	Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16, 271-278; discussion 278-284.
[22]	Brayne C, Gao L, Dewey M, Matthews FE (2006) Dementia before death in ageing societies--the promise of prevention and the reality. PLoS Med 3, e397.
[23]	Brayne C, Gill C, Paykel ES, Huppert F, O'Connor DW (1995) Cognitive decline in an elderly population--a two wave study of change. Psychol Med 25, 673-683.
[24]	Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, Mistur R, Tsui WH, de Leon MJ (2008) Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging, in press.
[25]	Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E, Aronson MK, Crystal HA (1994) Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol 88, 212-221.
[26]	Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T (2003) Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 106, 374-382.
[27]	Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2004) Cerebral white matter lesions and the risk of dementia. Arch Neurol 61, 1531-1534.
[28]	Sitoh YY, Sahadevan S (2004) Clinical significance of cerebral white matter lesions in older Asians with suspected dementia. Age Ageing 33, 67-71.
[29]	Gold G, Kovari E, Hof PR, Bouras C, Giannakopoulos P (2007) Sorting out the clinical consequences of ischemic lesions in brain aging: a clinicopathological approach. J Neurol Sci 257, 17-22.
[30]	Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ (2008) Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 64, 168-176.
[31]	Jellinger KA (2008) The pathology of "vascular dementia": a critical update. J Alzheimers Dis 14, 107-123.
[32]	Olichney JM, Hansen LA, Lee JH, Hofstetter CR, Katzman R, Thal LJ (2000) Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease. Ann N Y Acad Sci 903, 138-143.
[33]	Imhof A, Kovari E, von Gunten A, Gold G, Rivara CB, Herrmann FR, Hof PR, Bouras C, Giannakopoulos P (2007) Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? J Neurol Sci 257, 72-79.







Table 1. Characteristics of brain donors by clinical dementia status












Median age at death (IQR), years	90.3	87.7–93.0	91.2	88.0–93.8	90.7	88.0–93.4
Median follow-up time (IQR), years	9.5	7.6–13.1	8.7	5.9–12.2	9.2	6.7–12.5





Table 2. Distributions of preliminary neuropathology diagnoses (blind to clinical status) by observed clinical dementia status for first neuropathological diagnosis (Rank 1) and all diagnoses (All ranks). Numbers are expressed as the percentages of each neuropathological diagnosis by clinical dementia status at death. 


	No clinical dementia (n=100)		Clinical dementia (n=113)		Total (n=213)
















Table 3. Bivariable (adjusted for age) and multivariable (adjusted for all characteristics in the table) associations with clinical dementia

Characteristic	Number with characteristic	Bivariable analysis	Multivariable analysis
 	 	No dementia (n=100)	Dementia (n=113)	Odds ratio (95% CI)	p	Odds ratio (95% CI)	p
Age at death										
<90 years	44	(44%)	49	(43%)	1.0			1.0		
90-94 years	43	(43%)	42	(37%)	0.9	(0.5 - 1.6)		0.4	(0.2 - 1.1)	
95+ years	13	(13%)	22	(20%)	1.5	(0.7 - 3.4)	0.41	1.2	(0.4 - 3.4)	0.10
Time since last interview										
< 2 years	64	(64%)	64	(57%)	1.0			1.0		
≥ 2 years	36	(36%)	48	(43%)	1.3	(0.8 - 2.4)	0.30	2.2	(1.0 - 5.0)	0.05
Brain weight for sex										







Moderate or severe	8	(8%)	51	(45%)	10.0	(4.4 - 22.7)	<0.001	3.0	(0.8 - 10.9)	0.10
Hippocampal 									
None or mild	77	(78%)	48	(43%)	1.0			Not included	
Moderate or severe	22	(22%)	64	(57%)	4.7	(2.6 - 8.7)	<0.001			
Entorhinal cortex										
None or mild	89	(91%)	76	(68%)	1.0			1.0		







Moderate or severe	10	(10%)	31	(28%)	3.4	(1.6-7.4)	0.002	3.7	(1.2 - 10.8)	0.02
Entorhinal cortex										














Moderate or severe	4	(4%)	29	(26%)	8.6	(2.9-25.6)	<0.001	2.9	(0.6 - 14.0)	0.19
Cerebrovascular disease										
        Macroscopic atherosclerosis										
        None or mild	68	(71%)	71	(65%)	1.0			Not included	





















Yes	43	(43%)	60	(56%)	1.7	(1.0 - 3.0)	0.06	2.2	(1.0 - 5.1)	0.06
White matter pallor										
No	66	(66%)	50	(45%)				1.0		



























Table 4. Frequency of neuropathological findings by primary clinical diagnosis 

	Dementia (n=113)	




Mean age at death (SD), years	91.2	(4.0)	91.1	(4.6)	89.9	(5.9)	90.0	(6.1)	90.7	(4.5)



















































Table 5. Bivariable (adjusted for age) and multivariable (adjusted for all characteristics in the table) associations with clinical diagnoses including Alzheimer's disease and clinical diagnoses including Vascular dementia 

				Alzheimer's Disease*		Vascular Dementia*
						Bivariable analysis	Multivariable analysis				Bivariable analysis	Multivariable analysis
Characteristic	No dementia (n=100)	Cases (n=101)	Odds ratio (95% CI)	p	Odds ratio (95% CI)	p		Cases (n=29)	Odds ratio (95% CI)	p	Odds ratio (95% CI)	p
Age at death																			
<90 years	44	(44%)	42	(42%)	1.0			1.0				13	(45%)	1.0			1.0		
90-94 years	43	(43%)	40	(40%)	1.0	(0.5 - 1.8)		0.5	(0.2 - 1.2)			10	(34%)	0.8	(0.3 - 2.0)		0.7	(0.2 - 2.3)	
95+ years	13	(13%)	19	(19%)	1.5	(0.7 - 3.5)	0.53	1.0	(0.3 - 3.0)	0.29		6	(21%)	1.6	(0.5 - 4.9)	0.53	1.4	(0.3 - 6.0)	0.64
Time since last interview																			
< 2 years	64	(64%)	55	(55%)	1.0			1.0				14	(50%)	1.0			1.0		
≥ 2 years	36	(36%)	45	(45%)	1.4	(0.8 - 2.6)	0.21	2.8	(1.2 - 6.6)	0.02		14	(50%)	1.8	(0.8 - 4.2)	0.18	2.2	(0.7 - 6.6)	0.15
Neuritic plaques																			
Neocortical 																			
          None or mild	92	(92%)	53	(52%)	1.0			1.0				19	(66%)	1.0			1.0		
          Moderate or severe	8	(8%)	48	(48%)	10.6	(4.6 - 24.2)	<0.001	2.8	(0.8 - 10.6)	0.12		10	(34%)	5.9	(2.1 - 17.2)	0.001	6.2	(1.2 - 30.9)	0.03
Entorhinal cortex																			
          None or mild	89	(91%)	66	(67%)	1.0			1.0				24	(86%)	1.0			Not included	
          Moderate or severe	9	(9%)	33	(33%)	5.0	(2.2 - 11.4)	<0.001	4.8	(1.4 - 16.3)	0.01		4	(14%)	1.7	(0.4 - 6.5)	0.44			
Hippocampal diffuse plaques																			
None or mild	89	(90%)	68	(69%)	1.0			1.0				25	(86%)	1.0			Not included	
Moderate or severe	10	(10%)	31	(31%)	4.0	(1.8 - 8.7)	0.001	4.3	(1.4 - 12.6)	0.009		4	(14%)	1.5	(0.4 - 5.3)	0.52			
Neocortical tangles																			
None or mild	90	(90%)	48	(48%)	1.0			1.0				18	(62%)	1.0			1.0		
Moderate or severe	10	(10%)	53	(52%)	9.9	(4.6 - 21.2)	<0.001	4.8	(1.5 - 15.9)	0.01		11	(38%)	5.4	(2.0 - 14.8)	0.001	4.0	(0.9 - 16.7)	0.06
Congophilic amyloid angiopathy																			
 None or mild	96	(96%)	93	(92%)	1.0			1.0				28	(97%)	NA			NA		




Yes	43	(43%)	50	(52%)	1.5	(0.8 - 2.6)	0.19	1.8	(0.8 - 4.2)	0.18		22	(79%)	4.8	(1.8 - 13.0)	0.002	5.3	(1.6 - 17.3)	0.006
White matter pallor																			
No	66	(66%)	47	(49%)	1.0			1.0				13	(46%)	1.0			Not included	
Yes	34	(34%)	52	(53%)	2.3	(1.3 - 4.1)	0.006	1.9	(0.8 - 4.5)	0.13		15	(54%)	2.3	(1.0 - 5.5)	0.06			
Lewy bodies																			
No		91	(92%)	80	(79%)	1.0			1.0				23	(79%)	1.0			1.0		
Yes		8	(8%)	21	(21%)	3.3	(1.4 - 8.0)	0.008	4.6	(1.4 - 15.3)	0.01		6	(21%)	3.3	(1.0 - 10.5)	0.05	5.8	(1.5 - 22.4)	0.01
Hippocampal atrophy																			
None or mild	71	(75%)	45	(45%)	1.0			1.0				14	(48%)	1.0			1.0		
Moderate or severe	24	(25%)	55	(55%)	3.6	(1.9 - 6.6)	<0.001	3.6	(1.6 - 8.2)	0.002		15	(52%)	3.2	(1.3 - 7.6)	0.009	2.4	(0.8 - 7.1)	0.12
 







Figure 1. Distributions of (a) Braak staging and (b) CERAD staging in participants without clinical dementia (light grey) and with clinical dementia (dark grey).

Figure 2. Frequencies of (a) severity of congophilic amyloid angiopathy and (b) cerebrovascular disease pathology in participants without clinical dementia (light grey) and with clinical dementia (dark grey).

















* Rating of moderate or severe.
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